Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

被引:0
|
作者
Yu, Evan Y.
Joshua, Anthony M.
Shore, Neal D.
Kramer, Gero
Hu, Haixia
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
机构
[1] Univ Washington, Seattle, WA USA
[2] St Vincents Hosp Sydney, Sydney, NSW, Australia
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Med Univ Vienna, Vienna, Austria
[5] Merck & Co Inc, Rahway, NJ USA
[6] Royal Marsden Hosp NHS Fdn Trust, London, England
关键词
283-183-180-5577-2829-12292; 613-615-646-3281-7408-2638; 613-135-244-3829-325; 261-492-2769; 298-145-222-184-4809-5347; 261-566-9263; 283-183-143-3231-2482; 6; 5; 4; 3; 4082; 242; 256; 38092-25779; 1;
D O I
10.1200/JCO.2024.42.4_suppl.TPS250
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:TPS250 / TPS250
页数:1
相关论文
共 50 条
  • [1] Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Wu, Haiyan
    Schloss, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] KEYNOTE-365 cohort D: phase 1b/2 study of pembrolizumab plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer
    Appleman, Leonard
    Piulats, Josep
    Mar, Nataliya
    Arranz, Jose
    Joshua, Anthony
    Mayer, Tina
    Shore, Neal
    Wu, Haiyan
    Schloss, Charles
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [3] Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
    Yu, Evan Y.
    Kolinsky, Michael P.
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Appleman, Leonard J.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    Bogemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Linch, Mark
    Sridhar, Srikala
    Conter, Henry J.
    Laguerre, Brigitte
    Massard, Christophe
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian H.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2022, 82 (01) : 22 - 30
  • [4] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
    Arranz Arija, J. A.
    Yu, E. Y.
    Piulats, J. M.
    Gravis, G.
    Laguerre, B.
    Oudard, S.
    Fong, P. C.
    Kolinsky, M. P.
    Augustin, M.
    Todenhofer, T.
    Kam, A. E.
    Gurney, H.
    Tafreshi, A.
    Retz, M.
    Berry, W. R.
    Mar, N.
    Wu, H.
    Qiu, P.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S513 - S514
  • [5] KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arija, Jose Angel Arranz
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Feyerabend, Susan
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhofer, Tilman
    Laguerre, Brigitte
    Arranz, Jose A.
    Oudard, Stephane
    Massard, Christophe
    Heinzelbecker, Julia
    Nordquist, Luke T.
    Carles, Joan
    Kolinsky, Michael P.
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Qiu, Ping
    Poehlein, Christian H.
    Schloss, Charles
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2023, 83 (01) : 15 - 26
  • [7] Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony M.
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] PEMBROLIZUMAB plus LENVATINIB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS E/F
    Kramer, Gero
    Shore, Neal
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A449 - A449
  • [9] PEMBROLIZUMAB plus VIBOSTOLIMAB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS G/H
    Shore, Neal
    De Bono, Johann
    Kramer, Gero
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A455 - A455
  • [10] Pembrolizumab Combination Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer: Cohorts A-C of the Phase 1b/2 KEYNOTE-365 Study
    Joshua, Anthony M.
    Gurney, Howard
    Retz, Margitta
    Tafreshi, Ali
    Fong, Peter
    Shore, Neal
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Berry, William R.
    Kolinsky, Michael Paul
    Sridhar, Srikala S.
    Conter, Henry Joacob
    Todenhofer, Tilman
    Appleman, Leonard J.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    de Bono, Johann S.
    Yu, Evan Y.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 46 - 47